"At Houston Methodist Dr. Mary and Ron Neal Cancer Center in the Texas Medical Center, we treat every aspect of your cancer. Leading oncologists work with our specialists across disciplines to minimize cancer s effects on major organs. Our compassionate and supportive care team offers expert cancer services including screenings, genetic testing, second opinions, diagnostics, cutting-edge treatments and technology, access to clinical trials and patient support. We are home to five nationally recognized cancer programs and also have special strength treating breast cancer, blood cancers, lung cancer, liver cancer, genitourinary cancers, gastrointestinal cancer and neurological cancer."

During the past decade, Houston Methodist Cancer Center conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 21 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 17 clinical trials were completed. i.e. 94.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Houston Methodist Cancer Center" #1 sponsor was "The Methodist Hospital Research Institute" with 9 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "Celgene" with 4 trials sponsored, "Seagen Inc." with 3 trials sponsored and "Gilead Sciences" with 3 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Houston Methodist Cancer Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator and "Eli Lilly and Company" with 2 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Houston Methodist Cancer Center" are "Breast Cancer" (10 trials), "Metastatic Breast Cancer" (4 trials), "Triple Negative Breast Cancer" (4 trials), "Non-Small Cell Lung Cancer" (3 trials) and "Lymphoma" (2 trials). Many other conditions were trialed in "Houston Methodist Cancer Center" in a lesser frequency.

Most popular intervention types in "Houston Methodist Cancer Center" are "Drug" (49 trials), "Biological" (6 trials), "Other" (5 trials), "Procedure" (4 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (8 trials), "Gemcitabine" (5 trials), "Capecitabine" (4 trials), "Docetaxel" (4 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Houston Methodist Cancer Center" are 43 trials for "All" genders and 12 trials for "Female" genders.

Currently, there are NaN active trials in "Houston Methodist Cancer Center". undefined are not yet recruiting, 14 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Houston Methodist Cancer Center, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Houston Methodist Cancer Center, 10 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".